DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Darzalex Faspro (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.)– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Darzalex Faspro® (daratumumab and hyaluronidase-fihj), a subcutaneous... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 15, 2021 Category: Drugs & Pharmacology Source Type: news

Positive Phase 3 Trial in hATTR Amyloidosis With Polyneuropathy Positive Phase 3 Trial in hATTR Amyloidosis With Polyneuropathy
The RNAi therapeutic vutrisiran met its primary and secondary endpoints in the HELIOS-A phase 3 study of patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 9, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

New treatment uncovered for AL amyloidosis to be announced at ASH Meeting
(SWOG) Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that isatuximab, a monoclonal antibody approved for the treatment of multiple myeloma, can effectively treat relapsed refractory AL amyloidosis, findings to be announced at the 2020 Annual Meeting of the American Society of Hematology (ASH), held virtually December 5-8, 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news

Inotersen less costly for treatment of polyneuropathy in hereditary amyloidosis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2020 Category: Drugs & Pharmacology Source Type: news

Utility of Biomarkers in Cardiac Amyloidosis Utility of Biomarkers in Cardiac Amyloidosis
This paper presents an overview of the utility of cardiac biomarkers in determining disease progression, response to therapies, and prognosis in patients with cardiac amyloidosis.JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 27, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Racial/ethnic minorities comprise small portion of patients referred with AL amyloidosis
(Boston University School of Medicine) Despite being theoretically at an increased risk for AL amyloidosis, underrepresented minorities make up only a small percentage of patients seen at specialized treatment centers for this disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 10, 2020 Category: Cancer & Oncology Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Wall awarded $385,000 grant to study amyloidosis treatment options
(University of Tennessee Health Science Center) Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center's Graduate School of Medicine in Knoxville and director of the Amyloidosis and Cancer Theranostics, has been awarded a two-year grant totaling $385,000 from the National Institute on Aging, part of the National Institutes of Health to study new treatments for systemic amyloidosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 6, 2020 Category: International Medicine & Public Health Source Type: news

TTG Imaging Solutions to distribute MiE PET system
Diagnostic imaging equipment firm TTG Imaging Solutions has received exclusive...Read more on AuntMinnie.comRelated Reading: Groups ask NRC to allow virtual radiotracer training TTG Imaging acquires NIS ASNC, ASE win CMS recognition for ImageGuide Registry PET shows meditating increases blood flow in heart disease patients ASNC releases directive on cardiac amyloidosis imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 28, 2020 Category: Radiology Source Type: news

Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
Leverages proprietary pan-amyloid targeting agents with potential to diagnose and reverse the underlying pathology of systemic amyloid diseases, including AL and ATTR amyloidosis SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 -- (Healthcare Sales & Marketi... Biopharmaceuticals, Venture Capital Attralus, amyloidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 14, 2020 Category: Pharmaceuticals Source Type: news

Outcomes in Patients With Cardiac Amyloidosis and ICD Outcomes in Patients With Cardiac Amyloidosis and ICD
This study compared survival in patients with cardiac amyloidosis with and without a primary prevention implantable cardioverter-defibrillator. Did an ICD improve outcomes?Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Transthyretin Cardiac Amyloidosis in Severe Aortic Stenosis Transthyretin Cardiac Amyloidosis in Severe Aortic Stenosis
A new study explores whether it is feasible to perform TAVI in patients with aortic stenosis and probable concomitant transthyretin amyloidosis.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

New York man, 52, walks again after learning back pain was a rare form of HEART DISEASE 
Rick Weber, 52, from New York, learned that the pain in his back and legs was being caused by cardiac amyloidosis, abnormal protein deposits in his heart that didn't allow blood to flow properly. (Source: the Mail online | Health)
Source: the Mail online | Health - June 21, 2020 Category: Consumer Health News Source Type: news

New Option for AL Amyloidosis: Daratumumab Added to CyBorD New Option for AL Amyloidosis: Daratumumab Added to CyBorD
The addition of daratumumab to the standard CyBorD regimen produced'substantial'increases in hematologic response rates and delayed the time to organ failure.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Is the Main Cause of Amyloidosis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 5, 2020 Category: General Medicine Source Type: news

Untangling the Physiology of Transthyretin Cardiac Amyloidosis Untangling the Physiology of Transthyretin Cardiac Amyloidosis
A new study investigates echocardiographic phenotypes of transthyretin cardiac amyloidosis, the most common etiology of restrictive cardiomyopathy, identifying parameters predictive of survival.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 11, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Unbiased proteomic approach identifies pathobiological profiles in the brains of preclinical models of repetitive mild traumatic brain injury, tauopathy, and amyloidosis - Ojo JO, Crynen G, Algamal M, Vallabhaneni P, Leary P, Mouzon B, Reed JM, Mullan M, Crawford F.
No concerted investigation has been conducted to explore overlapping and distinct pathobiological mechanisms between repetitive mild traumatic brain injury (r-mTBI) and tau/amyloid proteinopathies considering the long history of association between TBI... (Source: SafetyLit)
Source: SafetyLit - April 6, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Study of rare genetic disorder that effects the eyes
(Shinshu University) Small gauge vitrectomy for vitreous amyloidosis and subsequent management of secondary glaucoma in patients with hereditary transthyretin amyloidosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 3, 2020 Category: International Medicine & Public Health Source Type: news

Drug Trial Snapshot: ONPATTRO
ONPATTRO is a drug for the treatment of nerve damage in adult patients with hereditary transthyretin-mediated amyloidosis. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 30, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Long Delays in Amyloidosis Dx, Even With Established Cardiac Care Long Delays in Amyloidosis Dx, Even With Established Cardiac Care
The underrecognized disease is rare and diagnosis complicated by a lack of awareness and heterogeneity of symptoms at presentation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2020 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

anti-cancer drug safe and effective for treating light chain (AL) amyloidosis
(Boston University School of Medicine) There's a new treatment option available for patients with AL amyloidosis: daratumumab. Studied in a prospective clinical trial, only one of the two clinical trials of this agent in AL amyloidosis worldwide, researchers have found this anti-cancer drug to be well tolerated and effective in patients with relapsed AL amyloidosis when used with appropriate pre- and post-infusion medications. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 27, 2020 Category: International Medicine & Public Health Source Type: news

ASNC, ASE win CMS recognition for ImageGuide Registry
The American Society of Nuclear Cardiology (ASNC) and the American Society...Read more on AuntMinnie.comRelated Reading: ASNC releases directive on cardiac amyloidosis imaging Imaging groups oppose cuts in myocardial PET rates ACC, ASE release echocardiography training guidance ASNC names Beanlands as president (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 22, 2020 Category: Radiology Source Type: news

Ionis Appoints Onaiza Cadoret-Manier As Chief Corporate Development and Commercial Officer
CARLSBAD, Calif., Jan. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of Onaiza Cadoret-Manier as chief corporate development and co... Biopharmaceuticals, Neurology, Personnel Ionis Pharmaceuticals, RNA-targeted, antisense, transthyretin amyloidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 9, 2020 Category: Pharmaceuticals Source Type: news

Treatment of Cardiac Transthyretin Amyloidosis: An Update Treatment of Cardiac Transthyretin Amyloidosis: An Update
This article presents an overview of several new pharmacological agents available to treat cardiac transthyretin amyloidosis, a rare and difficult to diagnose genetic disorder.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 1, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Subtle Cognitive Difficulties May Predict Amyloidosis
TUESDAY, Dec. 31, 2019 -- Individuals with objectively-defined subtle cognitive difficulties (Obj-SCD) have faster amyloid accumulation and faster entorhinal cortical thinning compared with cognitively normal (CN) individuals, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 31, 2019 Category: Pharmaceuticals Source Type: news

C2N Diagnostics Brings Home Positive Results for Alzheimer ’s Test
C2N Diagnostics’s detection test for Alzheimer’s disease is showing off some strong data coming out of the 12th Annual Clinical Trials in Alzheimer’s Disease conference. The St. Louis-based company said results from a study show the Aptus-Aβ test strongly predicts the presence of brain amyloidosis in a diverse population. C2N Diagnostics said its blood-based in vitro diagnostic is being developed to predict amyloid PET scan results. It combines into a ratio, the concentration of amyloid beta (Aβ) isoforms Aβ42 and Aβ40 in ...
Source: MDDI - December 10, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news

Medical News Today: What is amyloidosis?
Amyloidosis is a condition that causes abnormal proteins to grow on a person's organs. It can cause a variety of symptoms, depending on the organs involved. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 24, 2019 Category: Consumer Health News Tags: Endocrinology Source Type: news

Changes in the Blood Could Hold Key for Better Alzheimer ’s Detection
Researchers at the University of Turku have discovered new changes in blood samples associated with Alzheimer’s disease. A new study was conducted on disease-discordant Finnish twin pairs: one sibling suffering from Alzheimer's disease and the other being cognitively healthy. The researchers used the latest genome-wide methods to examine the twins' blood samples for any disease-related differences in epigenetic marks which are sensitive to changes in environmental factors. These differences between the siblings were discovered in multiple different genomic regions. Development of the late-onset form of Al...
Source: MDDI - October 15, 2019 Category: Medical Devices Authors: MDDI Staff Tags: R & D Source Type: news

AL Amyloidosis: Advances in Diagnostics and Treatment AL Amyloidosis: Advances in Diagnostics and Treatment
Recent advances have led to promising new diagnostic strategies and treatment options for AL amyloidosis.Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2019 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Cardiac amyloidosis — What is amyloid and how does it affect the heart
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - September 26, 2019 Category: Consumer Health News Source Type: news

Cardiac amyloidosis — Treatment options
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - September 26, 2019 Category: Consumer Health News Source Type: news

ASNC releases directive on cardiac amyloidosis imaging
The American Society of Nuclear Cardiology (ASNC) has published a set of recommendations...Read more on AuntMinnie.comRelated Reading: Imaging groups oppose cuts in myocardial PET rates ASNC names Beanlands as president ASNC releases new guidelines for SPECT MPI SNMMI, ASNC offer guidelines for myocardial perfusion imaging with PET ASNC, SNMMI advise on cardiac sarcoidosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 9, 2019 Category: Radiology Source Type: news

Transthyretin Cardiac Amyloidosis: The Truth Is Unfolding Transthyretin Cardiac Amyloidosis: The Truth Is Unfolding
New technologies have determined that transthyretin cardiac amyloidosis, once thought to be rare and untreatable, is more common than previously thought, and novel therapeutic options are emerging.Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 26, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

A vicious cycle of {beta} amyloid-dependent neuronal hyperactivation
β-amyloid (Aβ)–dependent neuronal hyperactivity is believed to contribute to the circuit dysfunction that characterizes the early stages of Alzheimer’s disease (AD). Although experimental evidence in support of this hypothesis continues to accrue, the underlying pathological mechanisms are not well understood. In this experiment, we used mouse models of Aβ-amyloidosis to show that hyperactivation is initiated by the suppression of glutamate reuptake. Hyperactivity occurred in neurons with preexisting baseline activity, whereas inactive neurons were generally resistant to Aβ-mediated hyperact...
Source: ScienceNOW - August 7, 2019 Category: Science Authors: Zott, B., Simon, M. M., Hong, W., Unger, F., Chen-Engerer, H.-J., Frosch, M. P., Sakmann, B., Walsh, D. M., Konnerth, A. Tags: Medicine, Diseases, Neuroscience r-articles Source Type: news

New Alzheimer's Blood Test 94% Accurate New Alzheimer's Blood Test 94% Accurate
When combined with age and APOE ε 4 status, the blood test is 94% accurate in detecting brain amyloidosis and may be a"game changer" for the field.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 2, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Blast-mediated traumatic brain injury exacerbates retinal damage and amyloidosis in the APPswePSENd19e mouse model of Alzheimer's disease - Harper MM, Hedberg-Buenz A, Herlein J, Abrahamson EE, Anderson MG, Kuehn MH, Kardon RH, Poolman P, Ikonomovic MD.
PURPOSE: Traumatic brain injury (TBI) is a risk factor for developing chronic neurodegenerative conditions including Alzheimer's disease (AD). The purpose of this study was to examine chronic effects of blast TBI on retinal ganglion cells (RGC), optic nerv... (Source: SafetyLit)
Source: SafetyLit - June 29, 2019 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

Takeda scraps late-stage amyloidosis study
Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals. (Source: Reuters: Health)
Source: Reuters: Health - June 5, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

TTR vs AL Cardiac Amyloidosis: Don't Rely on Imaging Alone TTR vs AL Cardiac Amyloidosis: Don't Rely on Imaging Alone
Drs Acharya, Grogan and Abou-Ezzeddine from Mayo discuss amyloid and TTR cardiac amyloidosis, with particular focus on diagnostic challenges and use of the pyrophosphate (PYP) scan.Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 5, 2019 Category: Cardiology Tags: Cardiology Roundtable Source Type: news

Is Renal Infarction Linked to Cardiac Amyloidosis? Is Renal Infarction Linked to Cardiac Amyloidosis?
First study of its kind finds renal infarction in cardiac amyloidosis may be more common than previously thought, especially in patients with acute kidney injury, but an expert questions the results.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 4, 2019 Category: Transplant Surgery Tags: Nephrology News Source Type: news

AI+AR Equals Altoida ’s Alzheimer’s Detection Solution
Altoida is combining artificial intelligence, machine learning, and augmented reality to help detect Alzheimer’s disease. The Houston, TX-based company has struck a chord with venture capitalists, raising $6.3 million in a series A round. The financing was led by M Ventures, the corporate venture capital arm of the science and technology company Merck KGaA, Darmstadt, Germany, with participation from Grey Sky Venture Partners, VI Partners AG, Alpana Ventures, and FYRFLY Venture Partners. The new capital will be used to further expand Altoida's presence worldwide with an immediate focus on commercializati...
Source: MDDI - May 31, 2019 Category: Medical Devices Authors: Omar Ford Tags: Assembly and Automation Source Type: news

Renal infarction is associated with acute kidney injury in patients with cardiac amyloidosis
(Elsevier) Systemic amyloidosis is a major cause of renal injury, mostly due to direct kidney damage caused by deposits of abnormal protein called amyloid, in the kidney parenchyma. In patients with cardiac amyloidosis, renal infarction is associated with acute kidney injury according to a new study in Mayo Clinic Proceedings, published by Elsevier. Investigators recommend that a diagnosis of renal infarction should be systematically considered in patients with unexplained acute kidney injury in the context of cardiac amyloidosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 15, 2019 Category: International Medicine & Public Health Source Type: news

FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis
May 06, 2019 -- On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 6, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Treatments for Heart Failure Caused by Rare Disease
MONDAY, May 6, 2019 -- Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules have been approved to treat adults with cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM), the U.S. Food and Drug Administration announced... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2019 Category: Pharmaceuticals Source Type: news

Two Drugs Approved for Cardiomyopathy Caused by Amyloidosis
Two different versions of tafamadis get the FDA ’s nod to treat a rare heart disease.  (Source: ConsultantLive)
Source: ConsultantLive - May 6, 2019 Category: Internal Medicine Authors: Valerie DeBenedette Tags: Cardiology Cardiovascular Diseases Heart Health Latest e-News New Products The Latest Source Type: news

FDA OKs Two Tafamidis Formulations for Rare Cardiomyopathy FDA OKs Two Tafamidis Formulations for Rare Cardiomyopathy
These are the first FDA-approved treatments for transthyretin-mediated amyloidosis cardiomyopathy, a rare and often fatal disease caused by deposition of amyloid fibrils in the myocardium.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 6, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the same active moiety, tafamidis, but they are not substitutable on a milligram to milligram basis and their recommended doses differ. (Source: World Pharma News)
Source: World Pharma News - May 6, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Molecules that prevent protein misfolding point to new type of therapy for AL amyloidosis
(Scripps Research Institute) Scientists at Scripps Research have identified a group of small molecules that prevent structural changes to proteins that are at the root of AL amyloidosis, a progressive and often fatal disease. The drug mechanism that the team identified is analogous to a different drug that also originated at Scripps Research: Tafamidis, which stabilizes the protein transthyretin to treat the most common systemic amyloid disease that affects the heart or other organs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2019 Category: Cancer & Oncology Source Type: news